BackgroundEndovascular treatment devices require compatible guide catheters to navigate complex vessels and anatomy. The Fubuki XF Long Sheath guide catheter (Fubuki XF) was developed with a 0.090-inch internal diameter with hydrophilic coating, an atraumatic rounded tip, and enhanced trackability and support with gradual shaft transition zones.MethodsWe retrospectively analyzed a prospectively maintained database of neuroendovascular patients treated using Fubuki XF at our center (July 2022─May 2023). Baseline/procedural characteristics were collected. Outcomes of interest included technical success (procedure completion with Fubuki XF without alternative guide catheter use) and peri-procedural complications.ResultsThis study included 60 patients (43.3% [26/60] female; mean age: 69.6 ± 9.7) presenting with stenosis (45.0% [27/60]), unruptured aneurysms (31.7% [19/60]), ruptured aneurysm (1.7% [1/60]), arteriovenous fistula (5.0% [3/60]), arteriovenous malformation (3.3% [2/60]), chronic subdural hematoma (3.3% [2/60]), stroke/emboli (6.7% [4/60]), vasospasm (1.7% [1/60]), or carotid web (5.0% [1/60]). Fubuki XF was used to deliver endovascular treatment devices for stenting (43.3% [26/60]), flow diversion (23.3% [14/60]), embolization (11.7% [7/60]), coiling (10.0% [6/60]), balloon angioplasty (10.0% [6/60]), and mechanical thrombectomy (1.7% [1/60]). The Fubuki XF tip was placed in the internal carotid artery in 38.3% (23/60) of cases. Technical success was achieved in all cases. One V1 non-flow-limiting dissection (not related to Fubuki XF) and one failed closure occurred (1.7% [1/60] each). No iatrogenic strokes or intraprocedural ruptures occurred.ConclusionWe used Fubuki XF to safely and effectively deliver a variety of compatible neuroendovascular devices. Fubuki XF was stable in all cases and locations, and there were no device-related complications or dissections.

中文翻译：

---

Fubuki XF长鞘引导导管在神经血管内手术中的应用：60例机构经验

背景血管内治疗装置需要兼容的引导导管来导航复杂的血管和解剖结构。 Fubuki XF 长鞘引导导管 (Fubuki XF) 的开发内径为 0.090 英寸，带有亲水涂层、无损伤的圆形尖端，并通过渐进轴过渡区增强了可跟踪性和支撑。方法我们回顾性分析了神经血管内患者的前瞻性数据库在本中心使用Fubuki XF进行治疗（2022年7月─2023年5月）。收集基线/程序特征。感兴趣的结果包括技术成功（使用 Fubuki XF 完成手术，无需使用其他引导导管）和围手术期并发症。结果本研究包括 60 名患有狭窄的患者（43.3% [26/60] 女性；平均年龄：69.6 ± 9.7）（ 45.0% [27/60]）、未破裂动脉瘤（31.7% [19/60]）、破裂动脉瘤（1.7% [1/60]）、动静脉瘘（5.0% [3/60]）、动静脉畸形（3.3%） [2/60]）、慢性硬膜下血肿（3.3% [2/60]）、中风/栓塞（6.7% [4/60]）、血管痉挛（1.7% [1/60]）或颈动脉蹼（5.0%） [1/60]）。 Fubuki XF 用于输送血管内治疗装置，用于支架置入 (43.3% [26/60])、血流改道 (23.3% [14/60])、栓塞 (11.7% [7/60])、弹簧圈栓塞 (10.0% [6]) /60]）、球囊血管成形术（10.0% [6/60]）和机械血栓切除术（1.7% [1/60]）。 38.3% (23/60) 的病例中，Fubuki XF 尖端被放置在颈内动脉中。所有案例都取得了技术上的成功。发生一例 V1 非流量限制性夹层（与 Fubuki XF 无关）和一例闭合失败（各 1.7% [1/60]）。没有发生医源性中风或术中破裂。结论我们使用 Fubuki XF 安全有效地输送各种兼容的神经血管内装置。 Fubuki XF 在所有病例和位置都很稳定，并且没有发生与设备相关的并发症或解剖。